医学
动脉粥样硬化性心血管疾病
内科学
心脏病学
冠状动脉疾病
疾病
冠心病
光学(聚焦)
冠心病
急性冠脉综合征
冠状动脉粥样硬化
重症监护医学
冠状动脉造影
梅德林
抗体疗法
风险评估
临床实习
作者
Antonino Imbesi,Antonio Greco,Davide Capodanno
标识
DOI:10.1080/14779072.2025.2564137
摘要
INTRODUCTION: Atherosclerosis, the primary cause of coronary artery disease (CAD), progresses through subclinical, chronic, and acute phases, culminating in acute myocardial infarction (AMI). Historically viewed as a lipid-driven disorder, it is now recognized as an inflammatory disease. Despite achieving optimal low-density lipoprotein cholesterol reduction, many patients experience residual cardiovascular risk, largely attributed to persistent inflammation. AREAS COVERED: A comprehensive literature search has been performed on PubMed, Web of Science and Cochrane, up to July 2025, with no significant restrictions. The review explores the role of inflammation in plaque progression and destabilization, discusses emerging biomarkers for risk stratification, and summarizes current and investigational anti-inflammatory therapies. Special attention is given to the evolving understanding of acute versus chronic post-AMI inflammation and how this distinction may guide therapeutic strategies. EXPERT OPINION: Anti-inflammatory therapy has reshaped the landscape of cardiovascular prevention, yet challenges remain in patient selection, timing, and target identification. Novel imaging techniques and artificial intelligence-driven risk models offer promising avenues for personalized therapy. Future efforts should focus on precision-based approaches that target detrimental immune activation while preserving reparative processes, ensuring maximal clinical benefit.
科研通智能强力驱动
Strongly Powered by AbleSci AI